Brian Lanman

Senior Director of Research at Amgen

Thousand Oaks, California, United States

About

- Medicinal chemist and project leader at Amgen, Inc. - >15 yrs Experience in academic and industrial organic synthesis - >15 yrs Experience as a mentor, supervisor, leader, and team-player - 36 Peer-reviewed publications, 55 patents/applications, 5 book chapters Specialties: - Medicinal chemistry - Solid- and solution-phase organic synthesis - Solid-phase peptide synthesis - GPCRs - Kinases - Protein-protein interactions - Covalent inhibitors - Inflammation - Oncology - Cardiovascular disease - Structure-based design - Research informatics - Combinatorial chemistry - Computational chemistry - Cross-functional management - External collaboration management - Hit-to-lead - Lead optimization

Experience

  • Amgen (19 yrs 9 mos)
    • Senior Director Research
      Apr 2024 - Present · 2 yrs 4 mos

    • Director Research
      Oct 2020 - Apr 2024 · 3 yrs 7 mos

    • Principal Scientist
      Mar 2017 - Oct 2020 · 3 yrs 8 mos

      Project team lead for late-stage cardiovascular project (50+ person team). Chemistry lead (early & late optimization) for sotorasib (AMG 510) KRAS G12C covalent inhibitor program (15+ person chemistry team); delivered clinical development molecule on record timeline. Extensive modeling and research informatics experience (Maestro, MOE, Spotfire, Pipeline Pilot, Gaussian, in silico predictive models, etc.). Direct supervisor of six-person chemistry team.

  • Postdoctoral Fellow at UC Irvine
    2004 - 2006 · 2 yrs

    Advisor: Larry Overman. Developed novel synthetic methods to access the bis-guanidine marine natural product palau’amine.

  • Medicinal Chemistry Intern at Schering-Plough Research Institute
    Jun 1996 - Aug 1996 · 3 mos